Taken together, activation of STING in the thymus independent of COPA syndrome leads to the escape of self-antigen–specific T cells that otherwise normally undergo negative selection, findings relevant for other immunoregulatory disorders and patients receiving small molecule drugs to modulate STING signaling during cancer immunotherapy. This evidence concerns the gene STING1 and cancer.